PRMT1 and chronic myelogenous leukemia, BCR-ABL1 positive: To test the effect of pharmacological inhibition of PRMT1 on the self‐renewal of LSCs, we sorted GFP+c‐Kit+ cells from the vehicle or MS023 treated primary CML mice and performed in vitro CFC/replating assay or in vivo disease reconstitution assay (Figure S7N, Supporting Information).